Question

In: Operations Management

Jessica Smith is the vice president of new drug development at Generic Phama, Inc, a pharmaceutical...

Jessica Smith is the vice president of new drug development at Generic Phama, Inc, a pharmaceutical research company in Boston, Massachusetts. One year ago, she filed an application with the Food and Drug Administration (FDA) to obtain approval of a new drug for treating cancer. Smith met Joe Spencer at a convention three months ago and invited him to her room at the hotel. The two parted ways. Spencer worked as the director for approval of new drugs at the FDA. Two weeks later, Spencer wrote Smith a letter on FDA letterhead stating, “It was nice to see your name cross my desk on our company’s application for approval of the new cancer drug. I’d really like to see you again. Why don’t you come visit me in Washington this weekend?”

Smith considered requesting that the petition be referred to another director at the FDA. However, she is concerned that the transfer would delay the approval process for at least a year. Smith’s chief scientist advised her that a key competitor plans to introduce a similar drug on the market in three months.

Are there any legal or ethical barriers to relationships between corporate officers and members of administrative agencies involved in reviewing or regulating corporate activity?

What should she do?   

What would you advise her to do if you were head of human resources or legal counsel for Generic Pharma, Inc.

Solutions

Expert Solution

Yes, there are legal and ethical barriers to relationships between corporate officers and members of administrative agencies involved in reviewing or regulating corporate activity because relationships may actually affect the decision of the department based on the statement of a member of the administrative agency so legally the relationship should not be used in the process of approval and ethically also this is not right because this is kind of a preference or bias that is created.

At present she cannot do anything rather than wait of the decision and if the decision is not as per what she expects and if she believes that it is because of the relationship that they possess then she should actually work this up to the higher management of FDA for clarification of the rejection.

As the head of HR I would have actually advised her not to reply to Joe Spencer and keep the message as a document for the time being and anything from him should be saved which my actually be used if the application is rejected based on the relationship. These documents can then be used as proof against Joe.


Related Solutions

Wilson pharmaceutical is planning a 100 million for development of a new cancer drug. the development...
Wilson pharmaceutical is planning a 100 million for development of a new cancer drug. the development will be financed with a combination of debt preferred equity and common equity. the firms current capitol structure which considers to be optimal consists pf 30% debt 20% preferred equity and 50% common equity. the firm can issue bond with a cost of 12% before tax. the investment banker expects to sell the issue at its $100 par value per stock with a $14...
Explain why a generic drug product can be a pharmaceutical equivalent but not identical to the...
Explain why a generic drug product can be a pharmaceutical equivalent but not identical to the brand drug product?
Scenario 2: Administrative Agencies and Ethics Brian Day is the vice president of new technology development...
Scenario 2: Administrative Agencies and Ethics Brian Day is the vice president of new technology development at Future Electronics in Southaven Mississippi. One year ago, he filed an application with the Federal Communications Commission to obtain approval for a new device using satellite technology. Brian met Jenice Brown at an electronics convention two months ago and invited her to his room at the hotel. The two parted ways. Brown worked as the director for licensing approval of new products at...
In a study to evaluate drug efficacy, the manufacturer of a new type of generic drug...
In a study to evaluate drug efficacy, the manufacturer of a new type of generic drug for treating a disease wants to investigate the effectiveness of this generic drug as compared to the traditional brand name drug, At the present time, the brand name drug is the only approved treatment for the disease. Patients diagnosed with the disease have low concentration of a specific factor in their blood. Treatment with the brand name drug will result in an increase in...
If you were a member of the drug development committee at a pharmaceutical sponsor, how would...
If you were a member of the drug development committee at a pharmaceutical sponsor, how would you draft a package insert indication for a new lipid lowering drug that is proven more potent than atorvastatin. The new drug is called lowerstatin.
Gama-Smith, a pharmaceutical company, develops new drugs for COVID-19 with other pharmaceutical companies that have the...
Gama-Smith, a pharmaceutical company, develops new drugs for COVID-19 with other pharmaceutical companies that have the appropriate production facilities. When Gama-Smith acquires a stake in a development project, it makes an initial payment to the other pharmaceutical company. It then makes a series of further stage payments until the drug development is complete and it has been approved by the relevant authorities. In the financial statements for the year ended 30 June 2019, Gama-Smith has treated the different stakes in...
XYZ Pharmaceutical, Inc. just got FDA approval for their new drug, Viagrina. The company has never...
XYZ Pharmaceutical, Inc. just got FDA approval for their new drug, Viagrina. The company has never paid a dividend, but they expect to pay one for the first time by the end of the year. The expected dividend is $3.00 per share and the company expects that dividend to increase at a rate of 20% for five years. After that, XYZ expects to see its dividend growth limited by the growth rate the US economy, which on average is 4.5%...
As the new vice-president of finance, you are considering refinancing existing bonds with a new issue....
As the new vice-president of finance, you are considering refinancing existing bonds with a new issue. You note in particular a bond issue that has the following details: Maturity value of bond issue $ 67,000,000 Time to maturity (in years) 10 Time since initial bond issue (in years) 8 Annual coupon rate on existing bond 12.0% Call Premium No call allowed during the first 5 years Starting call premium in year 6 11% Call premium declines by 0.5% per year...
Your company, DrugsRUs, has developed a generic angiotensin-converting-enzyme inhibitor, Vasotec, as a pharmaceutical drug used primarily...
Your company, DrugsRUs, has developed a generic angiotensin-converting-enzyme inhibitor, Vasotec, as a pharmaceutical drug used primarily for the treatment of hypertension and congestive heart failure. You are leading the regulatory strategy team and have been asked to describe the path to approval comparing introduction in the US versus Brasil. Please discuss the following: (1) Which agency or agencies will be responsible for approving/reviewing your Vastec drug: (a) before commercial introduction, and (b) after approval for commercialization/sale within the US., and...
You are the new Vice President of Human Resources at a Hospital. You are excited about...
You are the new Vice President of Human Resources at a Hospital. You are excited about your role and you have already been briefed on some of the most challenging organizational problems. Your focus is on employee retention. The National Health Care Retention Report (2019) revealed that total hospital turnover rate across the US is at 19% which is 0.9% greater than 2017. Overall, hospital turnover rates range from 5.3% to 36.3% (National Healthcare Retention Report, 2019). Your hospitals turnover...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT